The results of a phase 1 study published in the internationally acclaimed journal The Lancet Infectious Diseases show that an inhaled adenovirus conjugate COVID-19 vaccine (Ad5-nCoV) was well tolerated and had a similar antibody response and cellular immunity to intramuscular vaccination.
The Doctors of the Therapeutic Clinic of the Medical School of the National and Kapodistrian University of Athens, Theodora Psaltopoulou, Panos Malandrakis, Giannis Danasis and Thanos Dimopoulos (Rector of EKPA) summarize the relevant publication.
The analysis included 130 participants randomized to one of five groups: intramuscular vaccination (one or two doses), inhaled vaccination (high or low dose, two doses), or both (initially one intramuscular dose and one inhaled booster dose). ).
The primary safety point was the occurrence of side effects seven days after vaccination. In terms of immunity, the goal was to measure IgG antibodies against SARS-CoV-2 virus spike protein and virus neutralizing antibodies 28 days after the last dose. The most common side effects described were fever, fatigue, and headache, and were more common in those who received the vaccine intramuscularly.
One dose of inhaled vaccine, equivalent to one-fifth of the intramuscular dose, induces strong immunity, and after two inhaled doses the titer of neutralizing antibodies reached levels similar to those induced by an intramuscular dose. Thus, the authors conclude that the Ad5-nCoV inhaled vaccine needs further studies to confirm its safety and efficacy.
Source: protothema.gr